Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Winner

Bristol-Myers Squibb Company (BMY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.5%. By the end of trading, Bristol-Myers Squibb Company rose 41 cents (1.2%) to $35.02 on light volume. Throughout the day, 7.3 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10.4 million shares. The stock ranged in a price between $34.47-$35.03 after having opened the day at $34.48 as compared to the previous trading day's close of $34.61. Other companies within the Drugs industry that increased today were: Telik (TELK), up 36.8%, Palatin Technologies (PTN), up 16.6%, Rexahn Pharmaceuticals (RNN), up 15.4%, and Questcor Pharmaceuticals (QCOR), up 14.8%.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Bristol-Myers Squibb Company, a biopharmaceutical company, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $58.73 billion and is part of the health care sector. The company has a P/E ratio of 15.6, below the average drugs industry P/E ratio of 15.7 and below the S&P 500 P/E ratio of 17.7. Shares are down 1.8% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, one analyst rates it a sell, and eight rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

• You can view the full Bristol-Myers Squibb Ratings Report.

On the negative front, K-V Pharmaceutical Company (KV.B), down 16.9%, Amyris (AMRS), down 12%, K-V Pharmaceutical Company (KV.A), down 10%, and Savient Pharmaceuticals (SVNT), down 9.6%, were all losers within the drugs industry with Alexion Pharmaceuticals (ALXN) being today's drugs industry loser.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

For more information on Bristol-Myers Squibb Company click any of the following:

• Bristol-Myers Squibb Company Stock Price

• Bristol-Myers Squibb Company Analyst Ratings

• Bristol-Myers Squibb Company Key Stats & Profile

• Bristol-Myers Squibb Company Earnings

• Bristol-Myers Squibb Company Ratio Comparison

• Bristol-Myers Squibb Company Growth Rates

• Bristol-Myers Squibb Company Balance Sheet

• Bristol-Myers Squibb Company Cash Flow

• Bristol-Myers Squibb Company Income Statement